Tecos demonstrated that sitagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, was noninferior to usual care for T2D without sitagliptin, with no significant difference in cardiovascular outcomes, as measured by 3P-MACE, thereby confirming the null hypothesis. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.